Key Takeaways:
- Reports Q1 sales of $16.29 billion, beating estimates of $15.83 billion.
- Growth driven by strong performance of cancer drug Keytruda.
- Company narrows its financial outlook for the remainder of the year.
Back
Back
Merck Q1 sales top $16 billion on strong Keytruda demand
Merck & Co. (MRK) reported first-quarter sales of $16.29 billion, surpassing analyst consensus estimates of $15.83 billion on the continued strength of its blockbuster cancer drug, Keytruda.
In its first-quarter earnings release, the company confirmed the solid performance, which represents a significant beat and a positive signal to investors. The results reflect the company's ability to capitalize on its key pharmaceutical assets.
The top-line growth was primarily fueled by Keytruda, which has become a critical revenue driver for the pharmaceutical giant. The performance of new products also contributed to the better-than-expected results, helping to offset pressure from generic competition on other products in Merck's portfolio.
The strong quarter comes as peer AstraZeneca also reported a sales beat, indicating a resilient demand for key drugs across the pharmaceutical sector. However, Merck narrowed its financial outlook for the full year, a move investors will be watching closely.
The updated guidance suggests a more cautious stance for the coming quarters. Investors will be looking for more details on the company's next earnings call regarding segment margins and the long-term outlook for its drug pipeline beyond Keytruda.
This article is for informational purposes only and does not constitute investment advice.
[1] Alphabet ups 2026 capex to as much as $190 billion, expects to 'significantly increase' in 2027[2] Egetis Therapeutics AB (publ) (PDPHF) Q1 2026 Earnings Call Transcript[3] AZN Q1 earnings and sales beat, key drugs offset generic pressure[4] Merck beats quarterly estimates on strength of Keytruda and new products, narrows outlook
